Delivery Order SPE2DB22D1106-SPE2DB25FFCF9
- Not listed
- The Defense Logistics Agency awarded a $1,729.05 delivery order to AmerisourceBergen Drug Corp for Synvisc-One Syringe 6ML, a pharmaceutical product used in joint pain management. This firm fixed price contract, issued on July 29, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order specifies a place of performance in...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $19,398.41 on July 29, 2025, for the supply of Synvisc-One syringes (6mL, 1 unit). This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 25, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract requires no set-aside designation. This delivery order is issued under...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Synvisc-One syringes (6mL) with a ceiling value of $3,885.12 under a firm fixed-price contract type. The contract is non-set-aside and competitively awarded, with an ultimate completion date of July 22, 2025. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,370.86 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for knee osteoarthritis treatment. This non-set-aside, competitively awarded contract is scheduled for completion by July 21, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used in orthopedic and rheumatological applications. The contract, valued at $14,689.32, is a firm fixed price delivery order with an ultimate completion date of August 1, 2025. This award represents a non-set-aside, competitively awarded contract supporting the federal medical procurement needs of military and veteran healthcare systems....
- The Defense Logistics Agency awarded a delivery order valued at $11,568.32 to AmerisourceBergen Drug Corp for Synvisc-One syringes (6mL) on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed-price delivery order represents a non-competitive set-aside and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Synvisc-One is a hyaluronic acid-based injectable used for knee osteoarthritis treatment, indicating this procurement...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, Corporate Office Division. The contract, valued at $3,373.43, is for the supply of SYNVISC-ONE SYRINGE 6ML, a pharmaceutical product. The contract has an ultimate completion date of August 26, 2024 and is a firm-fixed-price delivery order. This award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,051.94 firm fixed-price delivery order is for the supply of SYNVISC-ONE SYRINGE 6ML, a medical product used in the treatment of osteoarthritis. The contract has an ultimate completion date of November 25, 2024 and was awarded on November 22, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite...
- This federal contract award is for the delivery of Synvisc-One syringes, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $22,172.76, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 10, 2024, with a completion date of January 11, 2024. The contract is a firm-fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which...
- The Defense Logistics Agency awarded a $6,529 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of six milliliter syringes of Synvisc-One. The single syringe order is to be delivered to the prime contractor's facility in Conshohocken, Pennsylvania by July 11, 2023 under contract number 4561454979. Amerisourcebergen will fulfill the Defense Logistics Agency's need for this medical device as part of its role on an indefinite-delivery/indefinite-quantity...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFCF9Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,012.91 on August 8, 2025, for the supply of Synvisc-One Syringe 6ML, a pharmaceutical product for joint pain management. This is a firm fixed price contract with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The delivery order is scheduled for completion by August 11, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a routine pharmaceutical supply transaction under AmerisourceBergen's larger prime IDC with DLA valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, a major pharmaceutical distributor and critical federal healthcare vendor, serves military and veteran healthcare systems through this comprehensive global pharmaceutical support vehicle. The company's extensive portfolio with DLA encompasses specialty medications, vaccines, medical devices, and other healthcare commodities across multiple therapeutic domains, supporting the Defense Health Agency and other federal healthcare customers worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 8/8/25 |